Donor leukocyte infusions (DLI) can reverse relapse of hematologic malignancy following allogeneic hematopoietic stem cell transplant (HSCT) in some cases. Little is known regarding the effectiveness of DLI in children who relapse after HSCT. We report outcomes of 49 children who received DLI for relapse after allogeneic transplant. Prognosis was particularly poor (0/14 responses) for patients relapsing within 6 months from transplant. DLI rarely induced remission when given as sole therapy for marrow relapse. One-year disease-free survival was 30% (6/20) in patients who received DLI as consolidation following chemotherapy. The development of GVHD grades 1-2 was associated with superior 3-year survival than patients who developed GVHD grades 3-4 (Po0.002). To determine the benefit of DLI, 45 children who received DLI for relapse (four children without matches were excluded) were compared to 1229 children with similar characteristics whose relapse was not treated with DLI. There was no difference in survival (P ¼ 0.30) once adjustments were made to account for the time from relapse to DLI. Although a few children achieved durable remissions when DLI was used as part of a post-relapse treatment strategy, DLI was unsuccessful in the majority of cases. Strategies may be better directed at preempting post transplant relapse.
Introduction
Children have superior survival following allogeneic hematopoietic stem cell transplant (HSCT) for hematologic malignancies compared to adults.
1 However, post transplant relapse remains a major problem for pediatric HSCT recipients. 2 Donor leukocyte infusions (DLI) have some efficacy in reversing post-HSCT relapse. 3, 4 Factors that may impact the likelihood of success include the disease, tumor burden at time of DLI, donor type, pre-DLI chemotherapy, cytokine mobilization of donor leukocytes, cell dose and the time from transplant to relapse. Most of these studies report outcomes after DLI in adult HSCT recipients. The majority of pediatric DLI reports consist of anecdotes and small case series. [5] [6] [7] [8] We present a comparative analysis of outcomes in 49 children who received DLI for post transplant relapse and 1229 children who did not receive DLI reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).
Materials and methods
Details were collected from 49 children at 19 centers who received DLI between July 1991 and December 1999 for post-HSCT relapse of a hematologic malignancy. The data on 25 patients were collected retrospectively, whereas 24 patients were part of an IRB-approved prospective multicenter trial. In the DLI-specific trial, patients with ALL, AML who were in hematologic relapse, and CML in accelerated or blast phase were given reinduction chemotherapy followed by DLI during the blood count nadir. The target CD3-positive cell yield was 1 Â 10 8 CD3 þ cells/ kg and the target CD34-positive cell yield was 2 Â 10 6 cells/ kg, with the CD3-positive cell dose taking precedence over the CD34-positive cell dose. There was no post-DLI immunosuppression. The patients whose data were retrospectively collected were treated in a more heterogeneous fashion. Major differences between the retrospective patients and the prospectively treated patients include the infusion of DLI without reinduction chemotherapy in 11 acute leukemia cases and the administration of DLI following peripheral blood count recovery in three cases. There were no statistically significant differences between the retrospective cohort and prospective patients with respect to median number of DLI infusions (1) or median cell dose infused (1 Â 10 8 CD3 þ cells/kg). Patients who received reinduction chemotherapy before DLI were more likely to be treated on the prospective trial, and generally received a G-CSF-mobilized product, but this difference between cohorts was not statistically significant. For the purposes of this analysis, both sources of data were pooled. Patients were considered evaluable for chronic GVHD, if they survived at least 100 days from the day of DLI.
For comparison purposes, a non-DLI cohort was created from the CIBMTR database. From a cohort of 5639 subjects p18 years who received HSCT for AML, ALL, CML, juvenile myelomonocytic leukemia, or myelodysplastic syndrome during similar time periods, a final cohort of 1229 patients relapsing post-HSCT but not treated with DLI was constructed by selecting patients with similar characteristics to the DLI cohort with regard to age, disease status and donor source.
Statistical analysis
Overall survival was calculated as the number of days from relapse to death or last contact. Survival estimates were calculated using a left-truncated version Kaplan-Meier method. Comparison between survival curves was performed by the log-rank test. Comparing survival probabilities in the DLI and non-DLI-treated groups required adjustment for two sources of bias: differences in time to treatment (time to DLI) and differences in baseline characteristics of patients. To address the first source of bias, which results from the fact that patients must survive a sufficient length of time after relapse for a DLI to be given, left-truncated statistical methods were used. To achieve this, at each time point, the risk set in the non-DLI cohort consists of all patients still under study, while the risk set in the DLI cohort includes only those with a waiting time to DLI less than the current time point and who are still under study. For the non-DLI-treated cohort, 163 (13%) children received second transplant after relapse. These patients were censored at the time of second transplant. To adjust for the differences in baseline characteristics, a left-truncated relative mortality model was used. 9 The pre transplant variables of disease type (acute leukemia/myelodysplastic syndrome versus chronic leukemia), disease state before the transplant (early, intermediate and advanced), donor type (matched related versus other) and age (410 versus p10 years) were considered in the comparison. Then each DLI patient was categorized based on these variables. For each category, a standard mortality rate since relapse was calculated from a non-DLI cohort using the IBMTR database. A relative mortality, a(t), due to DLI was calculated. If a(t)41, then the DLI patient had a higher mortality rate than the non-DLI patient. If a(t)o1, then the non-DLI patient had a higher mortality rate. The relative mortality a(t) ¼ 1 was used to compare the mortality rate between DLI and non-DLI patients. The Kaplan-Meier survival curves for DLI and non-DLI patients were compared by using the lefttruncated version log-rank test.
Results
Between July 1991 and December 1999, 49 patients less than 18 years at the time of hematological malignancy Table 1 . Forty-eight patients had a BM relapse and one had an isolated extramedullary relapse. In 39 cases, the evidence for BM relapse was based on morphology and in six on cytogenetic analysis alone. Three patients had extramedullary relapse (one each with additional cytogenetic or hematologic relapse, one with isolated extramedullary relapse) ( Table 2 ). The median time from HSCT to relapse was 7 months (range 1-116 months). Patients who relapsed within 6 months from transplant were more likely to have advanced disease than patients who relapsed later (P ¼ 0.01), but were not different in terms of type of leukemia. The median time from relapse to DLI was 45 days (6-683 days). Patients received a median cell dose of 1 Â 10 8 CD3 þ cells/kg, regardless of whether the donor was related (37) or unrelated (12) .
Outcomes
Pre-DLI therapy Outcomes were compared for the 34 patients with acute leukemia marrow relapse based on pre-DLI therapy. CR was achieved in 2/14 (14%) who received no therapy other than DLI compared to 10/20 (50%) who received systemic chemotherapy (19) or intrathecal chemotherapy (1) pre-DLI (P ¼ 0.03). One-year disease-free survival was 1/14 (7%) for those treated with DLI alone compared to 6/20 (30%) who received chemotherapy pre-DLI (P ¼ 0.11).
Time from relapse to DLI None of 14 patients who relapsed within 6 months from transplant responded to DLI. However, 9/35 (26%) who relapsed more than 6 months from transplant were disease free at 1 year (P ¼ 0.04).
GVHD post-DLI
Seven patients who died before day 30 without acute GVHD were censored at the time of death. Sixteen patients developed grades 1-4 acute GVHD. The cumulative incidence of grades 2-4 and 3-4 acute GVHD were 33% and 15%, respectively. All six patients with grade 3 or 4 acute GVHD died, but 6/10 patients who developed grades 1-2 GVHD were alive at a median of 3 years post-DLI. Survival for this selected group of patients who developed mild acute GVHD was superior to patients who developed severe GVHD, Po0.002. This finding was still significant after adjusting for the time to develop GVHD.
Outcome by disease type ALL. The 18 patients with an ALL relapse survived a median of 3 months (range: 2 days to 73 months) from the DLI ( Table 2 ). Thirteen died from leukemia without achieving remission. Four patients achieved remission with chemotherapy and were given DLI as consolidation. Two of these died from relapse (4 months and 3 years), one died from chronic GVHD and infection, and one remained in remission at 6 years post-DLI. The final patient, who had isolated testicular relapse, remained in remission 1 year following testicular radiation and DLI.
AML. Seventeen patients with AML relapse received DLI. One patient received intrathecal chemotherapy followed by DLI for an isolated CNS relapse 9 years after BMT. This patient remained in continuous remission 8 years after DLI. The 16 patients with marrow relapse survived a median of 5 months (range: 20 days to 55 months). Ten died from leukemia without achieving remission. Five patients achieved remission and were given DLI as consolidation and one achieved remission by DLI alone. Three survived in remission at 3, 13 and 55 months, the other three relapsed, all within 12 months.
CML. Eight patients with CML relapse received DLI. Three patients with cytogenetic relapse and one with hematologic relapse remained in CR 9 months to 6 years later. Four patients with either hematologic relapse (2) or cytogenetic relapse (2) did not respond to DLI. Salvage therapy with a second transplant was successful in two of these patients. Other hematologic malignancies. Neither of two patients with juvenile myelomonocytic leukemia responded to DLI as sole therapy. One of four patients with relapsed myelodysplastic syndrome, all treated with DLI alone, remained in remission 1 year later, the other three died from relapse.
Comparison with patients not given DLI To determine whether DLI improved survival, 1229 patients from the CIBMTR registry with similar characteristics were compared to 45 patients who received DLI (Tables 1 and 2 ). Two patients with juvenile myelomonocytic leukemia but lacking a match in the non-DLI cohort and two patients who were added to the DLI database after the CIBMTR comparison group was created were excluded. After adjusting the time from relapse to DLI, there was no difference in survival between the patients who received DLI and those who did not receive DLI (P ¼ 0.30) (Figure 1 ). Although our ability to detect a difference was underpowered, a survival benefit from DLI in children appears to be small.
Discussion
The management of post transplant relapse in children is important, but the lack of data has been a barrier to determine optimal treatment approaches. In this study, to maximize sample size, we combined data from both a retrospective data collection and a prospective clinical trial. However, this maneuver may have introduced bias given that there was more heterogeneity in the treatments given to the retrospective cohort. Small numbers of patients precluded subset comparisons with the non-DLI cohort, leaving open the possibility that certain subsets may have better outcomes with DLI than the entire cohort suggests. Thus, it is necessary to cautiously interpret the results of this study. Nonetheless, the overriding message from this study is that DLI did not result in survival benefit for the majority of children treated. A GVL effect with DLI is well-established, 10 even if it cannot be reliably induced with the current strategies. Our data, which applies to pediatric patients, suggests that any benefit, to the degree that it exists, is most likely to be found in patients who relapse more than 6 months post-HSCT and receive chemotherapy pre-DLI. Similar findings were seen in a prospective study of DLI for AML. 3 It is not possible to determine whether the initial remission was primarily from the pre-DLI chemotherapy, the DLI itself, or some combination of both. However, the low likelihood of achieving remission with DLI alone suggests that pre-DLI chemotherapy is important when utilizing this treatment approach, at least in cases with overt hematologic relapse. The patients who had prolonged survival after DLI generally developed mild acute GVHD, a finding consistent with observations that (1) GVHD is a surrogate for GVL 11 and (2) GVHD-related mortality increases with GVHD grade. 10 Although we were able to identify characteristics of the relapse that appear to correlate with survival, most of the children who received DLI for relapse died from their disease or toxicity of the treatment.
The lack of survival advantage in children who received DLI compared to a large, matched cohort of children who did not receive DLI is noteworthy. Admittedly, the interpretation of this analysis must take into account that we combined patients with a variety of diseases, relapse types and treatment strategies to maximize statistical power. It is possible that different results would be obtained from comparisons of larger, more uniform populations of children with post transplant relapse. One intriguing question is whether reinduction chemotherapy alone may have been equally efficacious as chemotherapy plus DLI, at least for patients who relapsed more than 6 months from their original transplant. The finding that mild GVHD correlated with survival does argue for a DLIinduced GVL effect, but a prospective trial of chemotherapy alone compared to chemotherapy plus DLI would be necessary to answer this question. In any event, the low success rate following DLI in this study suggests that other strategies to improve HSCT outcomes in children are needed. Newer strategies under development include infusions of activated DLI 12 or low-dose DLI augmented with biological agents such as interferon-a. 13 Alternatively, strategies directed at preventing relapse in the first place may be efficacious. For example, post transplant imatinib appeared beneficial at reducing the relapse rate in Philadelphia-chromosome positive ALL patients with detectable minimal residual disease. 14 The development of therapeutic approaches along these lines may ultimately be required to improve relapse-related mortality following allogeneic HSCT in pediatric patients.
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